- Arxada will invest CHF 20m in its Kouřim, Czech Republic plant.
- The investment will enhance infrastructure and expand technological options.
- The site supports the CDMO part of Arxada's Specialty Products Solutions business.
- The investment aims to meet growing customer demand and accelerate project timelines.
Investment Overview
Arxada AG, a global specialty chemicals business, is set to invest CHF 20m (€19mln) in its industrial biotechnological plant located in Kouřim, Czech Republic. This facility is part of the company's Specialty Products Solutions business, specifically serving the contract development and manufacturing organization (CDMO) sector.
Infrastructure and Capacity Expansion
The investment aims to address infrastructure debottlenecking, expand technological options, and significantly increase formulation capacity. These enhancements are driven by the growing customer base and the need to support more complex and technologically challenging projects.
Strategic Importance
Lukas von Hippel, VP of the CDMO Business Line at Arxada, emphasized the strategic importance of the Kouřim site. Since the implementation of a new strategy in May 2020, there has been a noticeable increase in customer demand for support in new projects. The business development and process development teams at Kouřim are instrumental in accelerating development and reducing time to market by over a year in some cases.
Customer Demand and Site Maintenance
Zdena Cermakova, Kouřim Site Head, highlighted the growing demand for CDMO projects in biotechnology. The site has received positive feedback for its maintenance standards, with an auditor recently praising it as exceptionally well-maintained. This recognition sets a high standard for the facility moving forward.
